•  
  •  
 

The Science Journal of the Lander College of Arts and Sciences

Abstract

In recent years, the number of women with obesity has skyrocketed, prompting revolutionary advancement in weight loss medication like glucagon peptide 1 receptor agonists (GLP-1 RAs). These relatively new medications have flooded the pharmaceutical market, and their impact on fertility, specifically in women with obesity, has gained much attention. Obesity places strain on the female reproductive system, often causing menstrual irregularities, poorer oocyte quality, and implantation failure due to endometrium abnormalities (Zhang et al., 2024). On the flipside, weight loss in obese infertile women is associated with improved chances of becoming pregnant and possibly natural conception before IVF treatment (Best et al., 2017). Recent data suggest that GLP1 receptor agonists may partially reverse these obesity-related fertility impairments by improving metabolic status, normalizing gonadotropin secretion, and enhancing ovulatory function (Jensterle, 2019).

Request Accessible Format
Need this file in a format that works better with assistive technology? Submit a request.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.